Already registered? Need to register? Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates
Podcast: Can we improve FH detectionListen
Hot off the Press

ODYSSEY Outcomes: alirocumab reduces cardiovascular events and death after ACS

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & ObjectivesMission StatementEditorial BoardPartnership & OutreachForthcoming Meetings
What will members gain?
eBook
Download NowUNIQUE FREE APPAdvances in lipid lowering - a clinical guide

News from 86th EAS Congress
Lisbon 5-8th May

EAS2018

Check back for the latest news on PCSK9 science and clinical studies.


News from ACC 2018

acc2018

VIDEO: The Word from ACC 2018: ODYSSEY Outcomes

Highlights from ACC.2018: Poster presentations

Most viewed
Most viewed
ODYSSEY Outcomes and FOURIER in context

Targeting PCSK9 inhibition to patients: Highest risk – highest benefit

Report: PCSK9 Forum Editor Professor Derick Raal (University of Witwatersrand, Johannesburg, South Africa) comments on this recent proposal.
Read the report

Video: Is number needed to treat a practical approach to rationalising PCSK9 inhibitor therapy?
Watch the video

Hot Topics

PCSK9 inhibition and neurocognitive effects: weighing up the evidence

Whether lowering LDL cholesterol levels affects cognitive function is a concern with PCSK9 inhibitors. Professor François Mach (Geneva University Hospitals, Switzerland) discusses the evidence, and what new studies add.

Report: EBBINGHAUS counters claim of neurocognitive effects
Read the report
Video: Do the PCSK9 monoclonal antibodies have neurocognitive effects?
Watch the video

From the Editors

PSCK9 inhibitor therapy- after the clinical trials, what can we learn to improve practice?PSCK9 inhibitor therapy- after the clinical trials, what can we learn to improve practice?

Anthony Wierzbicki

After the dust has settled from ACC 2018, Prof. Anthony S Wierzbicki, Guy’s and St Thomas’ Hospitals, London, UK discusses the latest data from the PCSK9 inhibitor trials that will aid risk stratification.

Read the article


FOURIER analysis: consistent benefit across the range of inflammatory risk

Read the article

Latest Views

PlayThe Word from ACC 2018: ODYSSEY Outcomes
The Word from ACC 2018: ODYSSEY Outcomes
PlayHighlights from ACC.2018: Poster presentations
Highlights from ACC.2018: Poster presentations
PlayWill the trial evidence now overcome barriers to the use of PCSK9 inhibition?
Will the trial evidence now overcome barriers to the use of PCSK9 inhibition?
PlayWill FOURIER and ODYSSEY Outcomes change LDL cholesterol goals in high-risk patients?
Will FOURIER and ODYSSEY Outcomes change LDL cholesterol goals in high-risk patients?
PlayDo FOURIER and ODYSSEY Outcomes align with the ESC/EAS Task Force guidance on practical use of PCSK9 inhibition?
Do FOURIER and ODYSSEY Outcomes align with the ESC/EAS Task Force guidance on practical use of PCSK9 inhibition?
PlayProfessor Stephen Nicholls (South Australian Health and Medical Research Institute, Adelaide, Australia): How do you interpret the mortality data from ODYSSEY Outcomes?
Professor Stephen Nicholls (South Australian Health and Medical Research Institute, Adelaide, Australia): How do you interpret the mortality data from ODYSSEY Outcomes?

Meet our Editorial Board

View all our Editorial Board Prof John ChapmanResearch Professor at the University of Pierre and Marie Curie Prof Henry GinsbergDirector, Irving Institute for Clinical and Translational Research Dr Michel FarnierClinician based at Point Medical, Dijon, France Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. The PCSK9 Education and Research Forum is focused on raising awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target. As part of its remit, PCSK9 Education and Research Forum offers healthcare professionals open access to electronic and multimedia platforms providing real-time reporting of significant developments and news; authoritative analysis and commentary; as well as an extensive library of accredited educational materials tailored to the differing needs of registrants.

Our Partnership and Outreach

Through its unique global network of researchers and clinicians, the PCSK9 Education and Research Forum connects academic institutions, research organisations and societies which share the Forum’s commitment to the reduction of CVD mortality and morbidity through improved management of atherosclerotic dyslipidaemia. The Forum builds on educational partnerships with such organisations through jointly sponsored symposia, as well as accredited research and educational programmes.
Educational Partners and Supporters
AmgenThe Medicines CompanySanofi RegeneronAmgenThe Medicines CompanySanofi RegeneronAmgenThe Medicines CompanySanofi RegeneronThe Medicines CompanySanofi Regeneron
© Copyright 2018 PCSK9 Forum. All rights reserved